Research and Markets: Hemophilia A Global Clinical Trials Review, H2, 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8839ca/hemophilia_a_globa) has announced the addition of GlobalData's new report "Hemophilia A Global Clinical Trials Review, H2, 2011" to their offering.

GlobalData's clinical trial report, "Hemophilia A Global Clinical Trials Review, H2, 2011," provides data on the Hemophilia A clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

SCOPE

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

KEY TOPICS

Hemophilia A Report Guidance

Clinical Trials by Region Clinical Trials by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by BRIC Nations

Clinical Trials by G7 Nations

Clinical Trials in G7 Nations by Trial Status

Clinical Trials by E7 Nations

Clinical Trials in E7 Nations by Trial Status

Clinical Trials by Phase In Progress

Trials by Phase

Clinical Trials by Trial Status

Unaccomplished Trials of Hemophilia A Subjects Recruited Over a Period of Time

Prominent Sponsors

Top Companies Participating in Hemophilia A Therapeutics Clinical Trials

Prominent Drug Comparison Clinical Trial Profiles

Clinical Trial Overview of Top Companies

REASONS TO BUY

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

For more information visit http://www.researchandmarkets.com/research/8839ca/hemophilia_a_globa



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:   Brazil  Europe  Asia Pacific  North America  South America  China  Russia  India

INDUSTRY KEYWORDS:   Health  Clinical Trials

MEDIA:

Logo
 Logo

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.